Meeting
2021 ASCO Annual Meeting
Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
Authors
Jessica Stuart
Brigham and Women's Hospital, Boston, MA
Jessica Stuart , Biagio Ricciuti , Joao Victor Machado Alessi , Mizuki Nishino , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9103)
DOI
10.1200/JCO.2021.39.15_suppl.9103
Abstract #
9103
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
First Author: Sharjeel Syed
Poster
2020 ASCO Virtual Scientific Program
Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.
First Author: Pankti Reid
Poster
2023 ASCO Breakthrough
The preventive effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors.
First Author: Derek Huang
Poster
2023 ASCO Annual Meeting
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
First Author: Yufan Liu